NCT01251029

Brief Summary

Acute kidney injury (AKI) is one of the most serious and frequent complication of general anesthesia. Patients suffer from chronic kidney diseases (CKD) predispose to develop AKI. CKD patients often need some surgical interventions that have been done under general anesthesia; they therefore have an increased probability to develop AKI. N-acetylcysteine (NAC), a thiol compound with antioxidant and vasodilatory properties, reduces oxygen free radical production, decreases pump-related ischemia-reperfusion injury and the levels of pro-inflammatory cytokines. NAC has been reported to protect the kidney from injury induced by contrast media, ischemia, and toxins. Present study aimed to explore the efficacy of NAC treatment to prevent deterioration in renal functioning in CKD patients undergoing major surgery under general anesthesia. Study will include about 200 CKD (eGFR (estimated glomerular filtration rate) less than 40) patients that should undergo surgical interventions under general anesthesia and will divide to 3 groups as follows: group 1- about 40 patients which should undergo major vascular surgery; group 2 - about 60 patients that suppose to undergo major orthopedic surgery (revision of total hip, revision of knee); group 3 - about 100 patients undergoing major abdominal surgery. Patients from each group will randomly divide in two sub-groups (A and B). Subgroup A will receive NAC twice (14-16h and 2h) before surgery and 12h after surgery. Subgroup B will receive placebo (saline). Markers for kidney function such as eGFR, creatinin, urea, electrolytes, cystatin C, NGAL (Neutrophil Gelatinase-Associated Lipocalin), urine albumin will measure before and after surgery in all patients. An additional blood samples for assessment of nitric oxide and cytokine levels will be taken from each patient before and after surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jan 2011

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 25, 2010

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 1, 2010

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2011

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2014

Completed
Last Updated

December 1, 2010

Status Verified

November 1, 2010

Enrollment Period

2.7 years

First QC Date

November 25, 2010

Last Update Submit

November 30, 2010

Conditions

Outcome Measures

Primary Outcomes (1)

  • parameters of kidney function

Study Arms (1)

sugar pil and saline

EXPERIMENTAL
Drug: N-acetylcysteineDrug: Siran (N-acetylcysteine)

Interventions

1200 mg orally; 600mg i.v.

sugar pil and saline
sugar pil and saline

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients suffering from chronic kidney disease that should undergo surgical interventions under general anesthesia

You may not qualify if:

  • pregnancy
  • single kidney
  • heart failure (NYHA class III-IV)
  • hepatic failure
  • mental diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assaf Harofeh Medical Center

Ẕerifin, 70300, Israel

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

Acetylcysteine

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CysteineAmino Acids, SulfurSulfur CompoundsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Murat Bahar, MD

    Assaf-Harofeh Medical Center

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 1
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

November 25, 2010

First Posted

December 1, 2010

Study Start

January 1, 2011

Primary Completion

September 1, 2013

Study Completion

January 1, 2014

Last Updated

December 1, 2010

Record last verified: 2010-11

Locations